Literature DB >> 9070840

In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method.

M Aoki1, R Morishita, J Higaki, A Moriguchi, I Kida, S Hayashi, H Matsushita, Y Kaneda, T Ogihara.   

Abstract

Although antisense strategy has been at the center of interest in gene therapy, little is known about application of this strategy to cardiac diseases because of the lack of a suitable delivery method into the heart. Therefore, we compared the transfection efficiency of antisense oligodeoxynucleotides (ODN) using HVJ-liposome method and direct transfer in in vivo transfer into heart. To investigate the cellular fate and localization of ODN, transfer of "naked" FITC-labeled antisense ODN or ODN enwrapped in HVJ-liposome complex were examined. Following in vivo transfer using direct injection as well as in vitro transfer, fluorescence rapidly disappeared within 1 day, whereas transfer by HVJ-liposome method resulted in sustained fluorescence localized in the nucleus for at least 1 week. Measurement of fluorescence also demonstrated a significantly higher level in myocardium transfected by HVJ-liposome method than direct transfer. The present study demonstrated that HVJ-liposome method is more efficacious for ODN delivery by prolongation of half-life of ODN, suggesting its usefulness for gene therapy in cardiac diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9070840     DOI: 10.1006/bbrc.1996.5762

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

Review 1.  Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals.

Authors:  David A Dean
Journal:  Am J Physiol Cell Physiol       Date:  2005-08       Impact factor: 4.249

Review 2.  The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.

Authors:  Traian V Chirila; Piroska E Rakoczy; Kerryn L Garrett; Xia Lou; Ian J Constable
Journal:  Biomaterials       Date:  2002-01       Impact factor: 12.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.